Drawing for CELLTRION

USPTO serial 79079370

CELLTRION

Reviewed by CopyMark Law Group

Reg. 3936764Status 739Registered
Filing date
Status date
Registration date
Mar 29, 2011
Examiner
EULIN, INGRID C
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CELLTRION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005[ Vaccines; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organ; agents affecting peripheral nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the peripheral nervous system; ] agents for immunity adjustment, namely, pharmaceutical preparations for the [ prevention and ] treatment of disorders of the immune system; biological preparations for medical purposes; [ amino acids for medical purposes; antibiotic preparations; agents for respiratory organs, namely, pharmaceutical preparations for the prevention and treatment of disorders of respiratory organs; chemotherapeutics; reagents for measuring Hepatitis B Surface antibody, namely, medical diagnostic reagents for detecting Hepatitis B surface antibody; diagnostic preparations for medical use; AIDS, acquired immune deficiency syndrome diagnostic agents, namely, diagnostic preparation for medical use; AIDS, acquired immune deficiency syndrome vaccines; agents affecting central nervous system, namely, pharmaceutical preparations for the treatment and prevention of disorders of the nervous system; veterinary vaccines; agents for tumor treatment, namely, pharmaceutical preparations for the treatment of tumor; agents for urogenital organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of urogenital organs; kits for protein test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a protein related to a disease; kits for gene test, namely, diagnostic kits, namely, primary reagents for detecting the presence of a gene related to a disease; ] biopharmaceuticals for the treatment [ and prevention ] of [ infectious diseases, tumor-related diseases, ] auto-immune diseases, [ hormone-deficiency diseases; ] biopharmaceutical preparations, namely, polypeptides, proteins, monoclonal antibodies, [ hormones for the treatment and prevention of infectious diseases, tumor-related diseases, auto-immune diseases, hormone deficiency diseases; ] biotherapeutic preparations and substances for medical purposes; biotechnological preparations for medical purposes; pharmaceuticals [ ; chemical preparations for pharmaceutical purposes, namely, chemical reagents for medical purposes; chemico-pharmaceutical preparations ]ACTIVE—
035Wholesale distributorships featuring pharmaceutical products; retail store services featuring pharmaceutical products; business intermediary services in the field of pharmaceutical products; wholesale distributorships featuring biopharmaceutical products; retail store services featuring biopharmaceutical products; business intermediary services in the field of biopharmaceutical productsACTIVE—
040Treatment of biopharmaceutical materials, namely, processing finished products from raw biopharmaceutical materials; treatment service of biopharmaceutical materials for others, namely, processing finished products from raw biopharmaceutical materials for others; contract manufacturing service for others in the field of biopharmaceuticals; contract manufacturing service in the field of pharmaceuticalsACTIVE—
042Pharmaceutical research and development; [ bacteriological research; biological research; research and development for new products for others; material testing; chemistry services, namely, chemistry consultation; chemical research and analysis; technology outsourcing services on biopharmaceuticals manufacturing, namely, conducting biopharmaceutical research services for others; consulting services in the field of biotechnology; pharmaceutical drug development services with animal cell; scientific research related to genetically modified plant; biotechnology research; ] biopharmaceutical research and development [ ; medical product testing; technology outsourcing services on selecting medicines, namely, conducting pharmaceutical research services for others ]ACTIVE—
044[ Rental of medical and health care equipment; medical product information, namely, providing an interactive holistic web site featuring health information and patient initiated, patient authorized, fee-for-service, holistic approach distance healing sessions based on the patient's specific set of symptoms, medical profile and medical record analysis and patient benefit information concerning organic and holistic products and services; medical clinics, namely, conducting clinical trials of new products for medical purposes; hospitals; medical assistance services; biopharmaceutical consulting service]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2023ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Dec 2, 2022ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jul 9, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 12, 2021CHLDCHANGE OF OWNER RECEIVED FROM IB—
Apr 1, 2021NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Apr 1, 2021C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Mar 24, 2021ES75TEAS SECTION 71 & 15 RECEIVED—
Mar 22, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 22, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 22, 2021EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Mar 22, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 22, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 22, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 29, 2020REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Dec 5, 2019RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 6, 2018INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Feb 22, 2018INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 22, 2018INPCINVALIDATION PROCESSED—
Feb 15, 2018INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 15, 2017NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jun 15, 201771.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Jun 15, 2017APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 28, 2017ES71TEAS SECTION 71 RECEIVED—
Mar 26, 2015ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Feb 25, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 12, 2012LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
May 25, 2012LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Jun 30, 2011FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 30, 2011FIMPFINAL DISPOSITION PROCESSED—
Jun 29, 2011FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 29, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 11, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 11, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 7, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 7, 2010ALIEASSIGNED TO LIE—
Nov 15, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 12, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 11, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 11, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 11, 2010TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 12, 2010GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 12, 2010GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 12, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 10, 2010TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 10, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 10, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 10, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 19, 2010UNDNUNDELIVERABLE MAIL - NO ACTION TAKEN—
Apr 9, 2010RFNTREFUSAL PROCESSED BY IB—
Mar 19, 2010MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 17, 2010RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 17, 2010RFRRREFUSAL PROCESSED BY MPU—
Mar 17, 2010RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 16, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 15, 2010DOCKASSIGNED TO EXAMINER—
Mar 15, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 11, 2010REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance